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Maturity onset diabetes of the young type 3 (MODY3) and hepa-
tocellular adenomas (HCAs) are associated with mutations in the
HNF1A gene. HNF1A codes for the transcription factor HNF1a,
which interacts with DNA as a homodimer or a heterodimer with
HNF1b, to regulate multiple cellular functions including glucidic
metabolism, lipidic transport, and detoxication.
We report three members of one family with a novel germline
in-frame deletion of HNF1A exons 2–3 identiﬁed initially using
array CGH and direct sequence analysis. All three family mem-
bers have MODY3 in association with primary liver cell tumours
(HCA, liver adenomatosis (LA), and hepatocellular carcinoma
(HCC)). Additionally, a high rate of infant mortality was observed
in the family.
The described family demonstrates a novel HNF1A mutation
associated with both benign and malignant primary liver cell
tumours and MODY3.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Maturity onset diabetes of the young type 3 (MODY3) is a non-
ketotic, autosomal dominantly inherited form of diabetes, charac-
terized by severely defective insulin secretion and a retained sen-
sitivity to sulfonylureas. MODY3 is associated with heterozygous
mutations in the HNF1A gene [1]. HNF1A codes for the transcrip-
tion factor HNF1a, which interacts with DNA as a homodimer or a
heterodimer with HNF1b [1] to regulate cellular function includ-
ing glucidic metabolism, lipidic transport, and detoxication [2].
HNF1a and HNF1b are present in embryonic tissues and have
been suggested to play a role in tissue differentiation and cell
lineage commitment [3].Journal of Hepatology 20
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E-mail address: john.mccall@otago.ac.nz (J.L. McCall).Hepatocellular adenomas (HCAs) are benign liver tumours,
typically occurring in pre-menopausal women and are associated
with glycogen storage disease and exposure to steroid hormones
including the oral contraceptive pill [4]. HCAs can occur as single
or, less commonly, multiple tumours in the liver; more than ten
HCAs in an otherwise normal liver is deﬁned as liver adenomatosis
(LA) [2].Whether solitary ormultiple, HCAs can be complicated by
haemorrhage, pain, and transformation to hepatocellular
carcinoma (HCC) [4]. HCAs have been categorised into molecular
subtypes and a proportion are associated with bi-allelic HNF1A
mutations either from two somatic mutations or from a germline
and a somatic mutation [5,6]. Thus an association exists between
HNF1A genemutations andbothMODY3andHCA, sometimeswith
both conditions occurring in the same individuals [7].
This report describes a MODY3 family with a previously unde-
scribed germline mutation that is associated with three different
phenotypes of primary liver tumour: HCA, LA, and HCC. This is
the only report to date of theseMODY3-associated tumour pheno-
types occurring in the same family and only the second report of a
germline HNF1A mutation in an HCC [7]. In addition, we report a
high incidence of unexplained infant mortality, which has not
been previously described in a MODY3 family. The infant mortal-
ity, cancer incidence, and location of the mutation in the DNA-
binding domain of HNF1A are suggestive of a dominant-negative
effect for this mutation on the function of the HNF1a homodimer.Materials and methods
Molecular studies
DNA was extracted from whole blood using the Quick-gDNA™ Blood Miniprep kit
(Zymo Research Corporation, Irvine, U.S.A.) as per the manufacturer’s instruc-
tions. To locate the boundaries of the deletion, a series of nested PCR amplicons
were designed between intron 1 and exon 4 using seven forward primers in
intron 4 and a single reverse primer (HNF1R located within exon 4). Primers
HNF3F (50-GTTGGAGAATCTGCCCTCAA-30) and HNF1R (50-CCGGAAGGCTTCT
TCTTTG-30) generated a 1136 bp amplicon spanning the deletion (the expected
wild type PCR product was 10,412 bp). This amplicon was directly sequenced
in both directions using the BigDye Terminator (ver. 3.1) sequencing kit and
an ABI 3730xl DNA Analyser.
When searching for the presence of the deletion in family members, the
HNF3F/HNF1R PCR reaction was multiplexed with a second reaction (using prim-
ers WTF [50-TCTGTGGGACGGGAGTAGAC-30] and WTR [50-CCCAGAGCTTCCT-
GAGTTTG-30]) that detected a control fragment of the HNF1a gene
corresponding to nucleotides 15,453–16,249 (RefSeq NG_011731.2).13 vol. 59 j 904–907
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Fig. 1. Pedigree of NZM1. The ﬁrst line under each family member is an individual number. Individual numbers consist of a generation number (roman numerals) followed
by an individual number within that generation. The second line shows age of death if known. A diagonal line is drawn through deceased patients. The proband is marked
with an arrow. Key: Top left shaded, diabetes; top right shaded, LA; bottom left shaded, HCC; bottom right shaded, HCA.
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Clinical report
Eleven of the 55 family members in family NZM1 have been pre-
viously diagnosed with diabetes (Fig. 1). The clinical expression
of diabetes is highly variable with age of onset, ranging from
age seven (case III:9) to age 75 years (case III:2), and treatment
varying from diet to insulin therapy. Consistent with MODY3,
most family members are of slim body habitus. Three members
of the family are known to have developed primary liver cell
neoplasia.
The male proband (case IV:19) presented acutely at the age of
31 years with rupture of a 105 mm  60 mm liver mass and
underwent an urgent left hepatectomy. He has a history of sulpo-
nylurea-controlled diabetes since the age of 10 years. Histology
conﬁrmed a ruptured HCA in an otherwise normal liver, and a
biopsy of a smaller right lobe lesion also showed HCA. Follow-
up imaging has demonstrated nine other HCAs under 15 mm
diameter, which have remained unchanged on follow-up MRI.
The proband’s mother (case III:11) presented at the age of
59 years with biliary colic, and ultrasound showed an incidental
4.5 cm mass in the liver conﬁrmed on CT. She had diabetes from
the age of 10 years treated with low-dose-insulin. The liver lesion
was initially misdiagnosed as focal nodular hyperplasia, however,
it increased in size and repeat imaging and biopsy showed a well
differentiated HCC in a normal underlying liver. The patient was
referred at that stage, but the tumour was unresectable (vascular
invasion and inﬁltration of portal structures) and she died at age
65.
The 57-year-old maternal aunt of the proband (case III:9) was
diagnosed with diabetes at the age of seven and had developed
multiple diabetic complications including retinopathy, nephropa-
thy, neuropathy, and coronary artery disease. In April 2011, she
had an abdominal ultrasound which detected a 15 mm solid
lesion in the liver. The MRI characteristics suggested either HCA
or HCC and the lesion increased to 19 mm on follow-up imaging.
She underwent resection and made an uneventful recovery.
Histology conﬁrmed HCA in an otherwise normal liver.Journal of Hepatology 201The HCAs in the proband and his aunt contained steatosis on
histology. All three family members were found to have the
HNF1a ex2-3del mutation.
Additional clinical observations
Four of the 55 family members identiﬁed in the pedigree died
within the ﬁrst 48 hours of life (cases III:3, III:12, III:15, and
IV:21) and one further child died in the 4th year of life (case
IV:22). No speciﬁc information was available about the cause of
death in these individuals.
HNF1a mutation detection
Blood DNA from the proband was screened for point mutations
and small indels in HNF1A by direct sequencing of PCR amplicons
covering the entire coding region and splice junctions. Screening
for large deletions and duplications in the gene was carried out
using a Roche Nimblegen 135 K custom comparative genomic
hybridisation (CGH) array. No signiﬁcant sequence variants were
observed, however, a deletion of exons 2–3 was detected with the
CGH array. The precise boundaries of the deletion were identiﬁed
by dideoxy DNA sequencing of a PCR amplicon generated using
primers (HNF3F and HNF1R) located in intron 1 and exon 4.
The deletion was 9276 nucleotides in length, corresponding to
nucleotides 10,702–19,977 of the HNF1a gene (RefSeq
NG_011731.2). The 50 end is situated in intron 1 and the 30end
in intron 3, leading to the complete deletion of exons 2–3. The
mRNA containing the deletion is predicted to remain in frame
and the subsequent protein would carry a deletion of 129 amino
acids (aa 110–238). This deletion would be restricted to HNF1a
DNA-binding domain, with the N-terminal dimerisation domain
and C-terminal transactivation domain predicted to be
unaffected.
To conﬁrm the presence of HNF1A ex2-3del in the proband’s
mother and maternal aunt, blood DNA from these individuals
was PCR ampliﬁed using the ﬂanking primers HNF3F/HNF1R. A
1136 bp amplicon, diagnostic for the deletion, was detected in
both patients (Fig. 2).3 vol. 59 j 904–907 905
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Fig. 2. PCR ampliﬁcation of two HNF1 sequences in family NZM1. The arrow
indicates the truncated 1136 bp HNF1 amplicon that is diagnostic of HNF1 ex2-
3del. The lower band corresponds to the 797 bp control amplicon that is
generated in a multiplex reaction with the diagnostic amplicon. The proband
(IV:15) and two other affected family members (III:9, III:11) exhibit both
amplicons. A wild type control (C) contains only the 797 bp control amplicon.
Case ReportDiscussion
The three phenotypes of primary hepatocellular neoplasia (HCA,
LA, and HCC) described in this report have all previously observed
patients with MODY3, but never before within the same family
[6,7]. The proband presented acutely with a ruptured HCA and
has multiple other lesions that are stable on follow-up, his
mother presented de novo with an HCC and her sister was found
to have an incidental HCA. All three have MODY3 and another
eight family members, out of 55, have a history of diabetes.
We also discovered a high incidence of infant mortality in
family NZM1 (4/55). High infant mortality has not been previ-
ously reported in association with HNF1A mutations or MODY3.
The three infant deaths in the third generation of the case family
occurred in the 1940s–1950s. In 1950, the infant mortality rate in
New Zealand was 28 per 1000 live births [9]. Interestingly, homo-
zygous HNF1a deﬁcient mice fail to thrive and suffer from prema-
ture death [1]. Similarly, early mortality is seen with all knockout
models of HNF1b, a protein that can form heterodimers with
HNF1a [10].
HNF1A mutations occur in about half of HCAs not associated
with MODY3, but are rare in HCCs [7]. In the vast majority of
hepatocellular neoplasms, the mutations are biallelic, consistent
with a tumour suppressor role for HNF1A [2,7]. About 30% of
patients with an HNF1A mutation-containing HCA carry a germ-
line HNF1A mutation in one allele [7]. Interestingly, not all HCAs
with germline HNF1A mutations have a somatic mutation in the
second allele [2]. This observation may be explained by haploin-
sufﬁciency as described for HNF1A mutations in renal clear cell
carcinomas, endometrial tumours, and colorectal tumours [11],
however, this seems unlikely in the liver given the rarity of
monoallelic HNF1Amutations in HCA. A second possibility is that
certain HNF1Amutations can exert a dominant-negative effect by
disrupting the function of the HNF1a protein dimer as has been
observed in vitro [12]. Since in-frame deletion of HNF1A exons
2–3 deletes much of the DNA binding domain without extending
into the dimerisation domain, this deletion may lead to a domi-
nant-negative effect on HNF1a function. This observation could
explain the high penetrance of liver tumours in NZM1 (although
additional mutations in modifying genes such as CYP1B1 are a
possibility and would also be consistent with the observed high906 Journal of Hepatology 201infant mortality) [13]. It is notable that the monoallelic germline
HNF1A mutations described previously in HCA were all missense
mutations that also occurred outside the dimerisation domain
and therefore may have encoded proteins that could dimerise
with the wild type protein but disrupt transcriptional function
[2]. This raises the possibility that MODY3 patients with missense
mutations or in-frame deletions or insertions outside the dimer-
isation domain have an elevated risk of developing liver neoplasia
compared to patients with truncating mutations or mutations in
the dimerisation domain.
To date only three of eleven known diabetic NZM1 family
members have had a primary liver tumour identiﬁed. This may
reﬂect incomplete penetrance of liver tumours in MODY3 indi-
viduals [4] or it may be that some of the diabetes in NZM1 is
not MODY3. Genetic testing for 55 other family members, includ-
ing eight with diabetes, is being undertaken by Genetic Health
Services New Zealand. Those found to have the HNF1A ex2-3del
will be offered liver screening.
The HCC in this family arose in an otherwise normal liver in
the absence of known underlying risk factors and is likely to have
arisen from an HCA that underwent malignant transformation.
Typically, HCAs have a very low risk of malignant transformation
(4–5%) [14], and there is only one previous case of HCC associated
with a germline HNF1A mutation (Gly574Ser) [7]. We therefore
speculate that if the HNF1A ex2-3del mutation causes a dominant
negative effect, then HCA formation might occur at a young age
(or in utero), increasing the time frame for malignant transforma-
tion. The importance of genotype-phenotype correlations in
HNF1A is supported by the observation that the position of the
mutation affects the age of onset of diabetes [15].
In conclusion, this paper describes a family with a novel in-
frame deletion of HNF1A exons 2–3 with co-existence of MODY3
and primary hepatocellular neoplasms (HCAs, LA, and HCC). The
complications endured by the family emphasise the importance
of testing for MODY3 in families with HCAs.Conﬂict of interest
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